《业绩》康方生物中期亏损扩至 5.7 亿人民币

Akeso (09926.HK) announced its interim results for the six months ending in June, with revenue recorded at RMB 1.412 billion, an increase of 37.7% year-on-year; gross profit was RMB 1.121 billion, up 18.8%, attributed to changes in commercial sales revenue. The loss widened from RMB 239 million in the same period last year to RMB 570 million, mainly due to increased investment loss provisions, R&D expenditures, and growth in equity incentive expenses; loss per share was 64 cents. No dividend was declared